Details of Orthocell’s upcoming ASX launch have been featured in the Australian Financial Review (AFR).
An excerpt from the article:
“Orthocell , a local biotechnology company that sells customised injectable human stem cell therapy for tendon injuries, is set to debut on the ASX in July as an $33 million company.
Up to 20 million shares are on offer in the float, priced at $0.40 per share to raise a maximum of $8 million. If the full amount is raised there will be a total of 77.5 million shares in the company at listing, giving it a market capitalisation of $82.5 million.”
Read the article HERE.